Finally, because all human epidemiologic data used for this study were obtained from patients with DKD who were receiving only an angiotensin-converting enzyme inhibitor and/or angiotensin II receptor blockers as part of their treatment regimen, we investigated whether the recent inclusion of sodium-glucose cotransporter 2 inhibitors in the standard care for DKD may affect the potential effectiveness of tozorakimab treatment. This evidence concerns the gene SLC5A2 and diabetic kidney disease.